Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs
Compose a Response to This Article
Other responses
No responses have been published for this article.
